v3.26.1
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)
6 Months Ended
Jun. 30, 2026
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES  
Schedule of research and development expenses

Three months ended June 30, 

Six months ended June 30, 

  ​ ​ ​

2026

  ​ ​ ​

2025

  ​ ​ ​

2026

  ​ ​ ​

2025

External clinical development expenses

$

2,475,836

$

1,637,683

$

4,959,301

$

3,334,914

Personnel related and stock-based compensation

 

1,027,495

 

258,072

 

1,749,752

 

687,490

Other research and development expenses

 

123,837

 

154,830

 

351,877

 

402,320

Total research and development expenses

$

3,627,168

$

2,050,585

$

7,060,930

$

4,424,724